Resonance Health patent granted
Thursday, 13 October, 2005
Perth based Resonance Health (ASX:RHT) has been granted its first European patent.
The patent protects the core invention underlying the FerriScan test for the non-invasive measurement of liver iron concentration. It is the European equivalent to a US patent granted in 2003 which is also being prosecuted in several other jurisdictions.
The company is also prosecuting a second patent family to expand the company's technology platform.
The intellectual property assets relating to the FerriScan test are fully owned by Resonance Health, following its acquisition of Inner Vision Biometrics in May 2005.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
